Notoginsenoside R1 (Sanchinoside R1),是一种从P. notoginseng中分离出来的皂苷。 Notoginsenoside R1 具有抗氧化,抗炎,抗血管生成和抗凋亡的活性。Notoginsenoside R1 可提供抗缺血/再灌注 (I/R) 损伤的心脏保护作用。Notoginsenoside R1 还可以提供神经保护作用。
生物活性 | Notoginsenoside R1 (Sanchinoside R1), a saponin, is isolated fromP. notoginseng. Notoginsenoside R1 exhibits anti-oxidation, anti-inflammatory, anti-angiogenic, and anti-apoptosis activities. Notoginsenoside R1 provides cardioprotection against ischemia/reperfusion (I/R) injury. Notoginsenoside R1 also provides neuroprotection in H2O2-induced oxidative damage in PC12 cells[1][2][3]. |
体外研究 (In Vitro) | Notoginsenoside R1 (2.5-80 μM; 24 h) inhibits the hypoxia-reoxygenation (H/R)-induced cell death, intracellular ROS accumulation, and mitochondrial membrane depolarization in H9c2 cardiomyocytes[1]. Notoginsenoside R1 (5-20 μM; 24 h) inhibits the H/R-induced H9c2 cardiomyocytes apoptosis in a concentration-dependent manner[1]. Notoginsenoside R1 (1-100 μM; 24 h) dose-dependently protects PC12 cells and primary neurons from Aβ-induced cell death and apoptosis[2]. Notoginsenoside R1 (10 μM; 24 h) inhibits Aβ25-35-induced ROS production, mitochondrial damage and MAPK activation in PC12 cells[2].
|
体内研究 (In Vivo) | Notoginsenoside R1 (5 mg/kg/h; infused via the right jugular vein) increases red blood cell velocity, reduces the number of adherent leukocytes and inhibits mast cell degranulation and cytokine elevation in rats[3].
Animal Model: | Male Sprague-Dawley (SD) rats (200-250 g)[3] | Dosage: | 5 mg/kg/h | Administration: | Infused 20 min before LPS infusion via the right jugular vein | Result: | Ameliorated the LPS-induced reduction in the mesenteric venular shear rate to some extent. Attenuated the LPS-induced adhesion of leukocytes to the venular wall. Inhibited mast cell degranulation and cytokine elevation. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
结构分类 | |
来源 | - Plants
- Araliaceae
- Panax notoginseng
|
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 100 mg/mL(107.17 mM;Need ultrasonic) 配制储备液 1 mM | 1.0717 mL | 5.3583 mL | 10.7166 mL | 5 mM | 0.2143 mL | 1.0717 mL | 2.1433 mL | 10 mM | 0.1072 mL | 0.5358 mL | 1.0717 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (2.68 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (2.68 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (2.68 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (2.68 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (2.68 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (2.68 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|